Business
Caliway Makes First ECO 2026 Oral Presentation on Preclinical Data of CBL-514 in Combination with GLP-1R-Based Weight-Loss Therapies, Attracting Strong Interest from International Experts and Global Pharmaceutical Companies for Its Systemic Metabolic Effects
Caliway Biopharmaceuticals (TWSE: 6919), a clinical-stage biopharmaceutical company advancing innovative small-molecule therapies in aesthetic medicine, metabolic diseases, and other unmet medical needs, announced that preclinical data on its first-in-class large-area localized fat reduction drug candidate, CBL-514, in combination with GLP-1R-based weight-loss therapies, were presented in an oral presentation on May 14 at the 33rd European Congress on Obesity (ECO 2026), held in Istanbul, Türkiy
About this update from Caliway Biopharmaceuticals Co Ltd
[{"type":"text","content":"CBL-514, when combined separately with two leading GLP-1R-based weight-loss therapies, semaglutide and tirzepatide, demonstrated enhanced weight loss, attenuated post-discontinuation weight regain, and greater reductions in subcutaneous and visceral fat in animal studies. The presentation also marked the first disclosure at an international congress of CBL-514's potential to improve liver metabolic indicators.","length":417,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Preclinical data on Caliway's localized fat reduction drug candidate CBL-514 in combination with GLP-1R-based weight-loss therapies were presented in an oral presentation at the European Congress on Obesity 2026 (ECO 2026) on May 14. The presentation was delivered by Arya M. Sharma, MD, an internationally recognized authority in obesity medicine and a scientific advisor to Caliway, who shared the potential scientific value of CBL-514 in weight loss, fat reduction, and metabolic applications with global experts in obesity and metabolism.","length":546,"tagName":"p"}]},{"val":[{"type":"text","content":"The study results showed that CBL-514, whether combined with semaglutide or tirzepatide, demonstrated higher weight reduction, attenuate post-discontinuation weight regain, and further reduce subcutaneous and visceral fat in animal studies.","length":240,"tagName":"p"}]},{"val":[{"type":"text","content":"This presentation also marked the first disclosure that, following the combination of CBL-514 with GLP-1R-based weight-loss therapies, improvements in hepatic lipid content, hepatic cholesterol, and liver histopathological indicators were observed in animal studies, providing additional scientific rationale and potential value for expanding CBL-514 from localized fat reduction into weight management and metabolic health applications.","length":437,"tagName":"p"}]},{"val":[{"type":"text","content":"The oral presentation attracted strong attendance, and following the session, Caliway engaged in further discussions with international experts in obesity and metabolism, as well as senior decision-making representatives from multinational pharmaceutical companies, indicating strong interest from the international academic and industry communities in the latest results of CBL-514 in combination with GLP-1R-based therapies.","length":426,"ta...